Diagnosing, monitoring and managing behavioural variant frontotemporal dementia

Olivier Piguet1,2, Fiona Kumfoe1,2, John Hodges1,3

Frontotemporal dementias (FTDs) are progressive neurodegenerative brain conditions characterised by brain atrophy in the prefrontal cortices or the anterior portions of the temporal lobes caused by various intraneuronal inclusions and abnormal protein depositions. FTD has a prevalence of 10–15/100,000 population in individuals aged 45–65 years, and is a common cause of younger onset dementia, although with large variability across studies.1,2 Recent evidence indicates that the occurrence of FTD beyond 65 years of age appears to be more common than previously assumed.3

Unlike Alzheimer disease (AD), the clinical profile and pathology of FTD are heterogeneous and characterised by two main phenotypes: a progressive deterioration in behaviour and personality, known as behavioural variant FTD (bvFTD); and a decline in language skills, known as primary progressive aphasia, which is further subdivided according to the main pattern of language breakdown into progressive non-fluent aphasia and semantic dementia.3,4 This review focuses on bvFTD. Although bvFTD is recognised as a potential cause of both major and mild neurocognitive disorder in the fifth edition of the Diagnostic and statistical manual of mental disorders,5 the international consensus criteria published in 20116 are usually preferred in the clinic.

Substantial clinical and pathological overlap exists between FTD and motor neuron disease (MND) as well as other extrapyramidal motor disorders. About 10% of patients with FTD have features of MND.6,7 Similarly, about 40% of patients with MND will develop behavioural or language deficits. In some instances, these deficits are severe enough to meet the FTD diagnostic criteria.6 FTD can also overlap with two other movement disorders — corticobasal degeneration and progressive supranuclear palsy — with which it shares abnormal tau pathology.6

Clinical presentation

The clinical presentation of bvFTD is that of progressive changes in personality, interpersonal conduct and emotion processing, which reflect the pathological changes in the brain networks supporting social cognition, emotion regulation, motivation and decision making (Box 1). This presentation contrasts with that of AD, where patients and their carers tend to report cognitive deficits, most commonly regarding episodic memory, while social graces remain relatively intact. As insight is commonly affected, it is crucial to interview a family member or a close friend to document the nature, severity, and progression of these early signs and symptoms. Additional information can be gathered from questionnaires aimed at carers.10-12 These questionnaires systematically probe for the presence and severity of various symptoms found in different types of dementia and are therefore helpful with differential diagnosis.10-12 What differentiates bvFTD from other dementias is not so much the presence of particular features, which are also found in other dementias, but rather their early presence and severity.

Summary

- Behavioural variant frontotemporal dementia is characterised by insidious changes in personality and interpersonal conduct that reflect progressive disintegration of the neural circuits involved in social cognition, emotion regulation, motivation and decision making.
- The underlying pathology is heterogeneous and classified according to the presence of intraneuronal inclusions of tau, TDP-43 or, occasionally, fused in sarcoma proteins. Biomarkers to detect these histopathological changes in life are increasingly important with the development of disease-modifying drugs.
- A number of gene abnormalities have been identified, the most common being an expansion in the C9orf72 gene, which together account for most familial cases.
- The 2011 international consensus criteria propose three levels of diagnostic certainty: possible, probable and definite. Detailed history taking from family members to elicit behavioural features underpins the diagnostic process, with support from neuropsychological testing designed to detect impairment in decision making, emotion processing and social cognition. Brain imaging is important for increasing the level of diagnosis certainty over time. Carer education and support remain of paramount importance.

The presence of socially inappropriate behaviours (eg, disinhibition, socially inappropriate comments), stereotypical motor behaviour, and changes in eating habits (eg, increased food intake, hyperorality) are features that most clearly help distinguish bvFTD from AD in the early stages of the disease.13,14 As the condition advances, agitation and general irritability (ie, shortness of temper) seem to become more frequent, generally mixed with periods of apathy,15,16 while restlessness and hyperorality remain common throughout.17 Importantly, psychiatric elements such as delusions, paranoid ideation and hallucinations are relatively rare in bvFTD, except in patients harbouring the hexanucleotide repeat expansion in the C9orf72 gene, where psychosis has been documented in up to 40% of patients.18,19

Behavioural assessment is a crucial aspect of the examination when bvFTD is suspected. This investigation is sensitive and is a useful adjunct to the standard cognitive testing in helping to distinguish between bvFTD and AD. Although knowledge of the behavioural changes in bvFTD has increased markedly in recent years, the neural basis of these changes and their relation to underlying pathology remain poorly understood.

Cognitive profile of patients with bvFTD

In the early stages, patients with bvFTD may perform relatively well on formal tests of cognition, despite their personality and behavioural changes. The Mini-Mental State Examination is insensitive, but general screening measures that assess the major

1 Brain and Mind Centre, University of Sydney, Sydney, NSW. 2 School of Psychology, University of Sydney, Sydney, NSW. 3 Sydney Medical School, University of Sydney, Sydney, NSW.

Narrative review

MJA 2017 (7) • 2 October 2017

1 Symptoms characteristic of behavioural variant frontotemporal dementia

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Clinical characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apathy</td>
<td>Very common; manifests as inertia, reduced motivation, lack of interest in previous hobbies, and progressive social isolation</td>
</tr>
<tr>
<td>Disinhibition</td>
<td>Often coexists with apathy; produces impulsive actions leading to overspending, tactless or sexually inappropriate remarks, and a range of socially embarrassing behaviours</td>
</tr>
<tr>
<td>Repetitive or stereotypic behaviour</td>
<td>May be apparent with perseveration and a tendency to repeat phrases, stories or jokes</td>
</tr>
<tr>
<td>Hoarding</td>
<td>When severe can result in squalor</td>
</tr>
<tr>
<td>Mental rigidity</td>
<td>Common; patients may have difficulty adapting to new situations or routines</td>
</tr>
<tr>
<td>Blunting of affect</td>
<td>Frequent reduction in range of emotional expression; elevation of mood resembling hypomania may also be seen</td>
</tr>
<tr>
<td>Changes in eating behaviour</td>
<td>Impaired satiety; change in preferences towards sweet food; common dysregulation of food intake</td>
</tr>
<tr>
<td>Loss of empathy</td>
<td>Common early symptom; lack of empathy towards others; inappropriate or subdued grief reaction</td>
</tr>
<tr>
<td>Other symptoms</td>
<td>New onset pathological gambling; hyper-religiosity (rare)</td>
</tr>
</tbody>
</table>


domains of cognition, such as the Addenbrooke’s Cognitive Examination\(^{20}\) offer improved detection.\(^{21}\) Performance on tasks assessing executive function may be variable despite being a central diagnostic feature.\(^{4}\) This variability may, in part, reflect the breadth of executive functions (eg, planning versus inhibition versus reasoning), and associated divergent neuroanatomical correlates. Tasks assessing disinhibition (eg, Hayling test) or generativity (eg, verbal fluency) appear particularly sensitive to bvFTD,\(^{22,23}\) and recent attempts to develop short executive function batteries have also shown promising results.\(^{23,24}\) Experimental tasks adopted from neuroeconomic theory, which focuses on behaviours such as social decision making, small short term gain versus larger long term gain, and aversion to monetary loss, have also shown promise. These tasks, which directly tap decision-making capacity, have helped further characterise the cognitive deficits seen in this syndrome.\(^{25,26}\)

Relative sparing of episodic memory has long been considered a defining feature, and is recognised in the current diagnostic criteria;\(^{4}\) however, episodic memory capacity is variable, with some patients showing a similar amnestic profile to that seen in AD.\(^{27}\) Indeed, a small proportion (10–15%) of patients with bvFTD present with severe memory deficits, which affect all aspects of episodic memory such as novel information learning, personal (autobiographical) memory, and tests of future thinking.\(^{28}\) Nevertheless, assessment of topographical memory (eg, supermarket orientation task) shows promise in differentiating bvFTD from AD.\(^{29}\)

Disturbance of emotion processing and emotion regulation is another diagnostic criterion for the disease (ie, early emotional blunting, early decline in social interpersonal conduct).\(^{4}\) This clinical profile, together with recognition of overlap between the pattern of atrophy in bvFTD and the “social brain”\(^{30}\) has led to a rapid emergence of research on social cognition, including emotion recognition, theory of mind and empathy, in bvFTD over the past decade.

In contrast to patients with AD, those with bvFTD show widespread early deficits in social cognition. Early research has found a striking facial emotion recognition deficit early on.\(^{31}\) Difficulties in recognising emotions are observed across a range of modalities (eg, photos, films, voices) and extend to complex emotions, such as embarrassment.\(^{32}\) The extent that a decline in face processing capacity may compound emotion recognition impairments has recently been explored, with some evidence that face and emotion processing interact.\(^{33}\) Performance on some emotion recognition tasks appears to be compounded in part by the presence of additional cognitive deficits.\(^{34}\) These cognitive deficits may be amenable to retraining, which would potentially improve emotion processing as well as have a positive impact on interpersonal interactions.

Complex social cognition is also reduced in bvFTD, affecting varied skills such as theory of mind (ie, ability to infer intention and mental states in others), detection of social faux pas, discrimination of sincere from sarcastic exchanges, and moral judgement.\(^{35}\) The loss of empathy and coldness commonly reported by carers\(^{36}\) has further been demonstrated on objective measures, such as the Empathy for Pain task\(^{37}\) and the Multifaceted Empathy Task.\(^{38}\)

Recently, deficits of social cognition have been interpreted as an inability to process and integrate relevant contextual information.\(^{39}\) This was in part driven by the observation that despite carers reporting profound changes in behaviour and social recognition, evidence of these behaviours can be difficult to elicit in the clinic. This apparent contradiction seems to reflect the fact that clinicians often become the patient’s “frontal lobes” during testing (eg, providing a focused, distraction-free environment). Hence, tests that incorporate contextual information and reflect ecological situations will be important for future research to examine. Clinically suitable tests of emotion and sarcasm detection exist,\(^{40,41}\) which also track disease progression.\(^{42}\) Thus, integration of social cognition tests is essential to complement the typical cognitive assessment in individuals where a differential diagnosis of bvFTD is considered.

Structural and functional neuroimaging

Early bilateral anterior brain atrophy (orbitofrontal, anterior cingulate, frontal insula) is observed on neuroimaging in bvFTD.\(^{43}\) Changes are not limited to the grey matter and the cortical surface, with additional involvement of the frontal white matter tracts, in particular those connecting subregions within the frontal lobe (eg, genu of the corpus callosum) or those connecting frontal and temporal brain regions (eg, uncinate fasciculus).\(^{44}\)

The region comprising the anterior cingulate and frontal insula cortices contains von Economo cells. This unique population of neurons, which is involved in the development and maintenance of social cognition, is severely reduced in patients with bvFTD at autopsy.\(^{45}\) Patients with bvFTD experience additional changes in structural and functional connectivity in these regions sensitive to early atrophy, and more so than patients with other forms of dementia (Box 3, A).\(^{46,47}\) Although the location and severity of grey matter atrophy has been suggested to be predictive of the underlying pathology in bvFTD, the location and severity of the brain atrophy appear to relate more closely to clinical features than to specific pathologies.\(^{48}\)
Reduction in functional and structural connectivity in subcortical structures (eg, amygdala, striatum, thalamus) have also been documented. Over time, grey and white matter changes become increasingly widespread and include posterior brain regions. This pattern is in contrast to the progression of atrophy in AD, which tends to follow a reverse posterior-to-anterior gradient (Box 3, B and C).

Differential patterns of brain atrophy have been found in the genetic forms of bvFTD, with a more bilateral anterior temporal profile in patients carrying a MAPT mutation, compared with an increased parietal involvement in patients carrying a GRN mutation. Studies of patients with the C9orf72 expansion suggest a mild cortical atrophy with cerebellar involvement, with some patients exhibiting very little, if any, atrophy at first presentation. Recent investigations of asymptomatic carriers of genetic abnormalities have demonstrated that changes in structural brain integrity may be present up to 15 years before the onset of clinical signs.

In most cases, atrophy in the frontal regions (medial, orbitofrontal and anterior insula) can easily be observed visually on magnetic resonance imaging (MRI) acquired in the coronal plane. Importantly, however, a seemingly normal MRI on visual inspection does not entirely rule out a diagnosis of bvFTD, as early changes may be subtle.

Functional neuroimaging is a helpful adjunct to diagnosis. Frontal hypoperfusion on hexamethylpropyleneamine oxime single-photon emission computed tomography is commonly seen in bvFTD. This pattern of hypoperfusion contrasts with that found in AD, which predominantly involves the temporoparietal and posterior cingulate brain regions. A consistent and reliable anterior–posterior contrasting profile of hypometabolism is found on fluorodeoxyglucose positron emission tomography (PET) between bvFTD (frontal) and AD (posterior) early in the disease process. This metabolic reduction on fluorodeoxyglucose PET is detected before any abnormalities are visible on structural MRI images, making it the most sensitive diagnostic tool currently available. Because focal frontal atrophy is a positive marker of FTD, little additional diagnostic benefit may be gained by conducting a PET scan in patients with clear brain atrophy on structural MRI.

In recent years, several β-amyloid-detecting PET tracers have been developed. These show promising results in discriminating between cases with and without underlying AD pathology (eg, [11C]-Pittsburgh compound B, florbetapir, florbetaben), particularly in patients presenting with aphasia rather than behavioural changes. Its use as a routine test remains to be established, as about 30% of cognitively intact individuals over the age of 70 years will return a positive scan. Some radiotracers targeting tau protein aggregations are available (eg, THK5351, AV1451) but currently lack the specificity required for broad clinical applicability. No radiotracer targeting transactive response DNA-binding protein 43 kDa (TDP-43) is currently available. In summary, neuroimaging investigations are useful diagnostic tests that can help differentiate

<table>
<thead>
<tr>
<th>2 Diagnostic classification of behavioural variant frontotemporal dementia and Alzheimer disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Behavioural variant frontotemporal dementia</strong></td>
</tr>
<tr>
<td><strong>Core clinical description</strong></td>
</tr>
<tr>
<td>Progressive deterioration of behaviour and/or cognition by observation or history</td>
</tr>
<tr>
<td><strong>Possible</strong></td>
</tr>
<tr>
<td>Three of the following behavioural/cognitive symptoms must be present; symptoms must be persistent or recurrent:</td>
</tr>
<tr>
<td>- early behavioural disinhibition</td>
</tr>
<tr>
<td>- early apathy or inertia</td>
</tr>
<tr>
<td>- early loss of sympathy or empathy</td>
</tr>
<tr>
<td>- early perseverative, stereotyped or compulsive behaviour</td>
</tr>
<tr>
<td>- hyperorality and dietary changes</td>
</tr>
<tr>
<td>- neuropsychological profile of executive deficits with relative sparing of memory and visuospatial function</td>
</tr>
<tr>
<td><strong>Definite</strong></td>
</tr>
<tr>
<td>Meets the criteria for either possible or probable bvFTD and either one of the following:</td>
</tr>
<tr>
<td>- histopathological evidence of frontotemporal lobar degeneration on biopsy or at autopsy</td>
</tr>
<tr>
<td>- presence of a known pathogenic mutation</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Probable</strong></td>
</tr>
<tr>
<td>Must meet all the following criteria:</td>
</tr>
<tr>
<td>- meets criteria for possible bvFTD</td>
</tr>
<tr>
<td>- exhibits significant functional decline</td>
</tr>
<tr>
<td>- brain imaging results show either reduced structural (atrophy on CT or MRI) or functional (hypoperfusion or hypometabolism) integrity in the frontal and/or anterior temporal cerebral regions</td>
</tr>
</tbody>
</table>

AD = Alzheimer disease; bvFTD = behavioural variant frontotemporal dementia; CSF = cerebrospinal fluid; CT = computed tomography; FDG = fluorodeoxyglucose; MRI = magnetic resonance imaging; PET = positron emission tomography; PiB = Pittsburgh compound B; R = Rascovsky K et al. 2017; 7: 263-269. This category is currently intended for research purposes.
bvFTD from other FTD subtypes and from other dementia syndromes.

**FTD pathology**

The neuropathologies of FTD are classified according to the distribution of protein accumulation in the brain, referred to as frontotemporal lobar degeneration (FTLD). In FTD, the brain exhibits frontotemporal atrophy in both hemispheres with neuronal loss, microvacuolation and variable astrocytic gliosis, as well as different types of protein accumulations.

The abnormal intracellular accumulation of the hyper-phosphorylated protein tau is found in about 40% of FTD cases (FTLD-tau). Tau is involved in cell stability and plays a central role in neuronal integrity. Tau-positive cases are further classified based on the types of inclusions, with either three or four microtubule-binding repeat tau inclusions. Most other cases are tau-negative and ubiquitin-positive, with inclusions comprising TDP-43 (FTLD-TDP). TDP-43 is involved in multiple aspects of RNA processing. About 5–10% of cases are tau- and TDP-43-negative and show fused in sarcoma (FUS) protein inclusions (FTLD-FUS). Finally, a small proportion of cases have either no inclusions or show ubiquitin inclusions which are TDP-43- and FUS-negative, suggesting that other protein abnormalities exist in FTD. In bvFTD, all neuropathological types are found; FTLD-tau and FTLD-TDP are detected in equal proportions, and there are a small number of FTLD-FUS cases. Currently, there are no reliable methods that enable the detection of pathology in life. With the development of disease-modifying therapies, however, accurate determination of pathology in vivo is becoming increasingly important.

**FTD genetics**

Up to 40% of patients with FTD have a positive family history of dementia with an autosomal dominant pattern of inheritance found in 10–20% of cases. Mutations on two genes found on chromosome 17 (MAPT and GRN) account for 5–12% of total FTD cases each. In 2011, a hexamino acid expansion on the C9orf72 gene was identified, which is now the most common gene abnormality in patients with FTD. This abnormality is very commonly associated with families presenting with a combination of either FTD, MND or a combination of both, as well as some apparently sporadic cases. Mutations in the VCP, CHMP2B, and TBK1 genes have been found to cause FTD, but these are rare.

From a clinical viewpoint, a detailed family history is recommended whenever FTD or MND is suspected, given the overlap between these two disorders. Clinical variability within families with the same gene mutation should also be considered. Indeed, one family member may present with bvFTD while others may have a progressive aphasia phenotype or a corticobasal syndrome. Screening for the presence of abnormality in the MAPT, GRN and C9orf72 genes is recommended in all patients with one or more first-degree relatives with a disease within the FTD spectrum, including MND. In the context of a combined presentation of FTD with MND, a family history of MND or features of psychosis, screening for C9orf72 mutation should be conducted first. Involvement of a clinician trained in genetic counselling or referral to an appropriate clinical genetics service is paramount.

**Management of patients**

There are currently no interventions or drugs that are specific for FTD. As such, treatment is mostly symptomatic, combining pharmacological and non-pharmacological measures, aimed at reducing the impact of debilitating symptoms. Evidence in support of pharmacological interventions in FTD is mixed. To date, only small treatment trials have been conducted, many of which have not considered the impact of the intervention on carer stress as a main outcome. These include trials of selective serotonin reuptake inhibitors to treat disinhibition and challenging behaviours, or atypical antipsychotics (eg, olanzapine) for agitation, aggressive behaviour or psychosis. Acetylcholinesterase inhibitors, commonly used in AD, do not show benefits in the treatment of FTD. Similarly, trials of memantine, a non-competitive inhibitor of N-methyl-D-aspartate receptors, have not shown any significant symptom improvement but a worsening in cognition. Recently completed double-blind, placebo-controlled trials of leuco-methylthioninium bis(hydromethanesulphonate), a drug targeting tau protein aggregation, failed to show any benefits in bvFTD or in AD.
In the absence of disease-modifying medications, non-pharmacological interventions remain the most appropriate action. Because of their reduced insight, difficult behaviours in bvFTD patients are best addressed using redirection or distractions and a predictable environment. Nevertheless, applications of novel technologies such as virtual reality to manage behaviour appear promising. In the later stages of the disease, direct interventions that target a particular symptom (eg, repetitive behaviour) have had positive outcomes. Although such interventions are highly individualised, they can be applied to any condition in which such symptoms are present.

Overall, the burden is much greater for carers looking after patients with FTD compared with other dementias, predominantly due to the behavioural changes present in bvFTD. In addition, a younger age at disease onset and increased disease severity also appear to contribute to the severity of burden in carers. Direct carer interventions (eg, carer support groups, behaviour management techniques and education about the disease) are promising avenues with evidence of success in reducing distress and improving coping strategies, as well as in understanding the disease. Importantly, aspects of carer health (eg, depression, psychological wellbeing) also contribute to carer stress.

**Final remarks and recommendations**

Our understanding of the phenomenology and pathology of bvFTD has improved considerably in the past 10–15 years. Prognosis, however, remains difficult and while the disease course is on average 5 years from the time of diagnosis, it is highly variable. The major challenge is now to improve the prediction of bvFTD neuropathology during life, which will also help to predict disease progression and duration. Research into disease biomarkers for the disease (eg, blood, cerebrospinal fluid) is promising but in its early days. Such research will become increasingly pertinent as novel pharmacological interventions are developed.

From a clinical viewpoint, clinicians (general practitioners, neurologists, psychiatrists) are encouraged to consider bvFTD as a possible diagnosis in the presence of progressive behavioural changes in middle life, particularly when combined with changes in eating habits or language disturbance. The combination of a detailed medical history, carer information, targeted neuropsychological testing (including investigations of social cognition) and brain neuroimaging will help to differentiate bvFTD from other dementia syndromes, or from psychiatric disorders (eg, major depressive disorder or bipolar disorder). Given the progressive nature of bvFTD, GPs have an important role to play throughout the disease course, as new symptoms emerge and others dissipate over time. We also recommend referral to dementia clinics that specialise in younger onset dementia, and support programs and services for patients with younger onset dementia. Organisations such as the Australian Frontotemporal Dementia Association and Dementia Australia, and international bodies such as the Association for Frontotemporal Degeneration in the United States and Dementia UK, provide valuable support for patients and carers.

**Acknowledgements:** Olivier Piguet is supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (APP1103258). Fiona Kiumfor is supported by an NHMRC–Australian Research Council Dementia Research Development Fellowship (APP1097026).

**Competing interests:** No relevant disclosures.

**Provenance:** Not commissioned; externally peer reviewed.